IRIDEX Corporation (IRIX)
Largest Insider Buys in Sector
IRIX Stock Price History Chart
IRIX Stock Performance
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems …
Insider Activity of IRIDEX Corporation
Over the last 12 months, insiders at IRIDEX Corporation have bought $0 and sold $0 worth of IRIDEX Corporation stock.
On average, over the past 5 years, insiders at IRIDEX Corporation have bought $68,980 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $6,200 was made by Devi Nandini () on 2022‑05‑20.
List of Insider Buy and Sell Transactions, IRIDEX Corporation
| 2022-05-20 | 2,000 0.0126% | $3.10 | $6,200 | -24.68% | ||||
| 2022-03-16 | 2,000 0.0122% | $4.20 | $8,400 | -41.86% | ||||
| 2021-12-02 | director | 1,644 0.0102% | $6.08 | $9,999 | -49.59% | |||
| 2021-11-16 | director | 1,000 0.0064% | $7.73 | $7,730 | -56.27% | |||
| 2020-05-15 | director | 15,125 0.1082% | $1.68 | $25,446 | +44.22% | |||
| 2019-11-18 | director | 14,600 0.0911% | $2.04 | $29,749 | +0.49% | |||
| 2019-11-15 | director | 10,000 0.0625% | $2.02 | $20,187 | +1.49% | |||
| 2019-11-14 | director | 10,000 0.0625% | $2.02 | $20,200 | +1.49% | |||
| 2019-11-13 | director | 5,000 0.0311% | $2.01 | $10,050 | +1.49% | |||
| 2018-12-13 | director | 863 0.0054% | $4.30 | $3,711 | -0.82% | |||
| 2018-12-12 | Chairman and CEO | 10,000 0.0642% | $4.34 | $43,443 | +0.59% | |||
| 2018-12-12 | director | 3,684 0.0235% | $4.32 | $15,903 | +0.59% | |||
| 2018-12-11 | director | 4,673 0.0298% | $4.18 | $19,542 | +3.78% | |||
| 2018-12-10 | director | 2,500 0.0156% | $4.17 | $10,432 | +1.55% | |||
| 2018-11-27 | Chairman and CEO | 10,000 0.062% | $4.71 | $47,144 | -8.11% | |||
| 2018-09-18 | 70,000 0.4375% | $6.00 | $420,000 | -22.00% | ||||
| 2018-09-14 | Chairman and CEO | 10,000 0.0613% | $6.56 | $65,600 | -29.97% | |||
| 2018-03-13 | Sale | 2,806 0.0166% | $5.86 | $16,444 | -6.77% | |||
| 2017-12-12 | Chairman and CEO | 5,000 0.0318% | $7.84 | $39,200 | -15.82% | |||
| 2017-09-15 | Chairman and CEO | 1,800 0.0109% | $9.42 | $16,956 | -23.20% |
Insider Historical Profitability
| BlueLine Catalyst Fund IX, L.P. | 2559122 15.3827% | $1.36 | 18 | 0 | +10.43% | |
| BlueLine Capital Partners II, L.P. | 10 percent owner | 2508100 15.076% | $1.36 | 2 | 0 | +27.27% |
| BlueLine Partners, L.L.C. | 10 percent owner | 2465222 14.8182% | $1.36 | 9 | 0 | |
| Acuta Capital Fund, LP | 10 percent owner | 1344720 8.083% | $1.36 | 33 | 0 | <0.0001% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 1320000 7.9344% | $1.36 | 17 | 0 | +39.25% |
Institutional Investor Ownership
| Paragon Associates Paragon Associates Ii Joint Venture | $2.98M | 6.15 | 1M | 0% | +$0 | 5.31 | |
| The Vanguard Group | $1.67M | 3.45 | 561,096 | +0.7% | +$11,613.06 | <0.0001 | |
| Amh Equity Ltd | $1.36M | 2.81 | 456,400 | +15.25% | +$179,992.00 | 1.76 | |
| Renaissance Technologies | $1.22M | 2.52 | 410,160 | -1.18% | -$14,598.69 | <0.01 | |
| Geode Capital Management | $359,765.00 | 0.74 | 120,694 | 0% | +$0 | <0.0001 |